Akums Drugs Q1 FY27 Results: Revenue Rs 1,166 Cr, PAT Rs 100 Cr and Key Highlights
- August 10, 2026
- Posted by: Lakshit Sharma
- Category: News
Akums Drugs Q1 FY27 results declared August 8, 2026. Revenue Rs 1,166 Cr (+13.93% YoY). PAT Rs 100 Cr (+56.11% YoY). CMP Rs 697.45 (+5.27%).
Akums Drugs Q1 FY27 results were announced on August 8, 2026, consolidated. Revenue grew +13.93% YoY to Rs 1,166 Cr from Rs 1,024 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 133 Cr (+45.15% YoY). PAT came in at Rs 100 Cr (+56.11% YoY), offering a comprehensive view of how Akums Drugs is navigating the current pharmaceuticals environment.
Click Here – Get Free Investment Predictions
Akums Drugs Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Akums Drugs Revenue | 1,166 | 1,024 | +13.93% |
| Operating Profit | 133 | 92 | +45.15% |
| Net Profit (PAT) | 100 | 64 | +56.11% |
| Reporting Basis | Consolidated | ||
Akums Drugs Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Akums Drugs Q1 FY27 results reflect strong fundamentals across key financial metrics. Revenue momentum stayed robust with the top line reaching Rs 1,166 Cr for the April to June 2026 quarter.
Operating profit expanded +45.15% YoY to Rs 133 Cr. This indicates improving cost efficiency and better product mix.
PAT of Rs 100 Cr marks a +56.11% YoY movement in Akums Drugs Q1 FY27 results. Investors monitoring Akums Drugs Q1 FY27 results will note this as a key FY27 performance milestone.
Key Business Factors in Akums Drugs Q1 FY27 Results
Revenue Expansion Driving Top-Line Growth
Akums Drugs Q1 FY27 results show top-line strength with revenue growing +13.93% YoY to Rs 1,166 Cr from Rs 1,024 Cr in Q1 FY26. Steady volume-led growth and disciplined pricing supported the revenue uptick.
Operating Leverage and Margin Improvement
Operating profit in Akums Drugs Q1 FY27 results improved +45.15% YoY to Rs 133 Cr, reflecting better cost control, improving product mix, and operating leverage as the company scales volumes.
PAT Performance and Profitability Trend
Net profit (PAT) in Akums Drugs Q1 FY27 results stood at Rs 100 Cr ((+56.11% YoY)). Improving PAT trajectory signals strengthening financial health.
Dividend Details
No dividend was announced alongside Akums Drugs Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.
FY27 Outlook for Akums Drugs
Akums Drugs is well-positioned to sustain growth momentum through FY27, backed by order visibility, sector tailwinds, and operational improvements. Management guidance points to continued expansion in the pharmaceuticals segment with a focus on margin improvement. Investors tracking Akums Drugs Q1 FY27 results should consult a SEBI-registered financial advisor before making investment decisions.
Akums Drugs Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Akums Drugs live price and get daily stock recommendations.
Akums Drugs shares were trading higher at Rs 697.45 (+5.27%) on August 8, 2026, reflecting investor sentiment on the Akums Drugs Q1 FY27 results and near-term sector outlook. The CMP of Rs 697.45 on the results date reflects broader market and sector sentiment in the pharmaceuticals space.
Key Risks for Akums Drugs
Sector-Specific Risks
USFDA regulatory actions, pricing pressure, and API cost inflation are core risks.
Valuation and Earnings Risk
Valuation risk if quarterly growth momentum fails to sustain over the next two to three quarters.
Operational and Financial Risk
Subsidiary-level losses or underperforming overseas operations could drag consolidated PAT lower.
Conclusion
Akums Drugs Q1 FY27 results reflect strong performance with revenue at Rs 1,166 Cr and PAT at Rs 100 Cr on a Consolidated basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Akums Drugs Q1 FY27 Results
When were Akums Drugs Q1 FY27 results declared?
Ans. Akums Drugs Q1 FY27 results were declared on August 8, 2026, covering the April to June 2026 quarter on a Consolidated basis.
What was Akums Drugs revenue in Q1 FY27?
Ans. Akums Drugs Q1 FY27 results show revenue of Rs 1,166 Cr, +13.93% compared to Rs 1,024 Cr in Q1 FY26.
What was Akums Drugs PAT in Q1 FY27?
Ans. Net profit in Akums Drugs Q1 FY27 results was Rs 100 Cr, +56.11% year-on-year.
Did Akums Drugs declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Akums Drugs Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.
What is the FY27 outlook for Akums Drugs?
Ans. Management has guided revenue growth and margin improvement for FY27. Sector trends and order visibility will be key monitorables for investors.
How did Akums Drugs stock react to Q1 FY27 results?
Ans. Akums Drugs shares were trading higher at Rs 697.45 (+5.27%) on August 8, 2026 following the Akums Drugs Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.